Advances in therapies for acute promyelocytic leukemia (Q37905921)

25 August 2017

1 reference

title

Advances in therapies for acute promyelocytic leukemia (English)

1 reference

25 August 2017

1 reference

Tomohiko Kamimura

1

1 reference

25 August 2017

Toshihiro Miyamoto

series ordinal

2

1 reference

25 August 2017

Mine Harada

series ordinal

3

1 reference

25 August 2017

Koichi Akashi

series ordinal

4

1 reference

25 August 2017

24 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

102

1 reference

25 August 2017

11

1 reference

25 August 2017

1929-1937

1 reference

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

25 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Acute promyelocytic leukemia--weapons of mass differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Acute promyelocytic leukemia: from highly fatal to highly curable

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Acute promyelocytic leukemia. Therapy results and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL9

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

All-trans-retinoic acid in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Retinoic acid syndrome: manifestations, pathogenesis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Modern approaches to treating acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Treatment of relapsed or refractory acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02045.X

10.1111/J.1349-7006.2011.02045.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference